Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.

Matoda M, Tanigawa T, Omatsu K, Ushioda N, Yamamoto A, Okamoto S, Kawamata Y, Kato K, Umayahara K, Takeshima N.

Int J Gynecol Cancer. 2013 Nov;23(9):1670-4. doi: 10.1097/IGC.0b013e3182a80a07.

PMID:
24172102
2.

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.

Takekuma M, Kuji S, Tanaka A, Takahashi N, Abe M, Hirashima Y.

J Gynecol Oncol. 2015 Jul;26(3):185-92. doi: 10.3802/jgo.2015.26.3.185.

3.

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.

Tanioka M, Katsumata N, Yonemori K, Kouno T, Shimizu C, Tamura K, Ando M, Fujiwara Y.

Cancer Chemother Pharmacol. 2011 Aug;68(2):337-42. doi: 10.1007/s00280-010-1494-7. Epub 2010 Oct 26.

PMID:
20976599
4.

Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.

Kimura T, Miyatake T, Ueda Y, Ohta Y, Enomoto T, Kimura T, Kamiura S.

Eur J Obstet Gynecol Reprod Biol. 2012 Oct;164(2):200-4. doi: 10.1016/j.ejogrb.2012.06.008. Epub 2012 Jul 4.

PMID:
22770633
5.

Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.

Hisamatsu T, Mabuchi S, Yoshino K, Fujita M, Enomoto T, Hamasaki T, Kimura T.

Int J Gynecol Cancer. 2012 May;22(4):623-9. doi: 10.1097/IGC.0b013e3182473277.

PMID:
22343974
6.

Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB.

Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cárdenas-Rebollo JM, Iodice S, Maggioni A.

Int J Gynecol Cancer. 2013 Nov;23(9):1647-54. doi: 10.1097/IGC.0b013e3182a616d2.

PMID:
24100590
7.

Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.

Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. Review.

PMID:
12654434
8.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.

PMID:
18977518
9.

Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.

Lee YY, Park W, Huh SJ, Yoon A, Park JY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS.

Anticancer Res. 2013 Oct;33(10):4675-81.

PMID:
24123048
10.

Chemotherapy for metastatic and recurrent cervical cancer.

Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006469. doi: 10.1002/14651858.CD006469.pub2. Review.

PMID:
23076924
11.

Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.

Paramanathan A, Solomon B, Collins M, Franco M, Kofoed S, Francis H, Ball D, Mileshkin L.

Clin Lung Cancer. 2013 Sep;14(5):508-12. doi: 10.1016/j.cllc.2013.03.007. Epub 2013 Jun 20.

PMID:
23792009
12.

Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study.

Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S, Ferrari F, Piovano E, Gadducci A.

Gynecol Oncol. 2014 Mar;132(3):611-7. doi: 10.1016/j.ygyno.2013.12.010. Epub 2013 Dec 14.

PMID:
24342439
13.

Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.

Adachi S, Ogasawara T, Tsubamoto H, Oku H, Hori Y, Tsuji Y, Takemura T, Koyama K.

Int J Clin Pharmacol Res. 2001;21(3-4):105-10.

PMID:
12067139
14.

Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.

Zanaboni F, Grijuela B, Giudici S, Cormio G, Babilonti L, Ghezzi F, Giorda G, Scambia G, Franchi M, Lorusso M, Ditto A, Lorusso D, Raspagliesi F.

Eur J Cancer. 2013 Mar;49(5):1065-72. doi: 10.1016/j.ejca.2012.10.008. Epub 2012 Nov 11.

PMID:
23151423
15.

[Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].

Yuan GW, Wu LY, Yao HW, Hou JL, Li XG, Liu LY.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):710-3. Chinese.

PMID:
20021871
16.

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V.

Gynecol Oncol. 2003 Jun;89(3):402-7.

PMID:
12798702
17.

A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma.

Dueñas-Gonzalez A, Lopez-Graniel C, Gonzalez A, Reyes M, Mota A, Muñoz D, Solorza G, Hinojosa LM, Guadarrama R, Florentino R, Mohar A, Meléndez J, Maldonado V, Chanona J, Robles E, De la Garza J.

Ann Oncol. 2001 Apr;12(4):541-7.

18.
19.

The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.

Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, Lou G, Li K.

J Surg Oncol. 2012 Feb;105(2):206-11. doi: 10.1002/jso.22052. Epub 2011 Aug 3.

PMID:
21815150
20.

Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix.

Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, Aslay I, Topuz E.

Int J Gynecol Cancer. 2003 Jul-Aug;13(4):497-504.

PMID:
12911727
Items per page

Supplemental Content

Write to the Help Desk